ERBB2 and breast carcinoma: Lapatinib (Figure 2), a synthetic quinazoline derivative, is an orally active reversible ErbB1 and ErbB2 tyrosine kinase receptor inhibitor that possesses antineoplastic activity towards breast cancer [39].